[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628243":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":48,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adaptive RT (Dose Painting)","EXPERIMENTAL","Participants in this arm will have radiation (with reduced margins) delivered using a dose painting approach",[13],"Radiation: Dose painting + Reduced Margins",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Dose painting + Reduced Margins","Reduced margins using a dose painting approach",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hanbo Chen, MD","CONTACT","416-480-6100","hanbo.chen@sunnybrook.ca",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Sunnybrook Health Sciences Centre - Odette Cancer Centre","RECRUITING","Toronto","Ontario","M4N3M5","Canada","CA",{"type":37,"coordinates":38},"Point",[39,40],-79.39864,43.70643,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":45,"phoneExt":46,"email":47},"Aimee Theriault","416-480-5000","67364","aimee.theriault@sunnybrook.ca",{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100628243","unity-based-mr-linac-guided-adaptive-radiotherapy-for-high-grade-glioma-4-100628243",false,"NCT07459101","UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4","UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4 (UNITED-4): Prospective Evaluation of FLAIR-Guided Clinical Target Volume Reduction","UNITED-4","Inclusion Criteria:\n\n* Histopathologically confirmed, based on biopsy or surgical resection, glioblastoma or WHO grade 4 astrocytoma (IDH wild type or mutant)\n* Deemed clinically appropriate for concurrent chemoradiotherapy (with temozolomide) with definitive\u002Fradical intent\n* Biopsy or surgical resection performed ≤ 12 weeks prior to study entry\n* Expected survival ≥ 12 weeks\n* ECOG performance status of 0, 1 or 2\n* Sufficient estimated glomerular filtration rate (eGFR) of ≥ 30 mL\u002F min\u002F1.73 m2 to allow administration of gadolinium-based contrast agent; patients with eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2 not on dialysis may be allowed on the study after discussion of risks and benefits and approval by study neuroradiologist(s)\n* Completed written informed consent\n* Patient must be accessible for treatment and follow-up\n* Patients with multifocal or multicentric disease will be allowed per the discretion of the radiation oncologist\n\nExclusion Criteria:\n\n* Contraindications to MRI examination as per standard MRI screening policy\n* Contraindication to Gadolinium-based contrast media\n* Enhancing disease involving any part of the brainstem on post-gadolinium T1-weighted MRI imaging for patients being treated using the short-course 15-fraction regimen\n* Inability to lie flat in a supine position for at least 30 minutes\n* Inability to tolerate immobilization in a head thermoplastic mask\n* Patients \\> 140 kg and\u002For a circumference \\> 60 cm (MRI scanner weight and bore size limits)\n* Prior therapeutic cranial irradiation\n* Leptomeningeal dissemination of disease\n* History of other malignancies with the exception of adequately treated non-melanoma skin cancer, or curatively treated other solid tumours with no evidence of disease for ≥ 2 years\n* Patients with any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol","ALL","18 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"NA","This study builds on the results of prior studies (UNITED and UNITED-3). The goal of UNITED-4 is to test whether an adaptive radiation therapy (RT) therapy approach ('dose painting'), with reduced margins, impacts approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive RT approach with reduced margins compares to standard RT in terms of:\n\n* Local control\n* Overall and progression-free survival\n* Patterns of failure\n* Toxicity, Neurological Function, and Quality of Life\n* Longitudinal imaging features",[68,69],"Glioblastoma (GBM)","Astrocytoma, Grade IV","2026-03-06",{"date":72,"type":73},"2026-03-09","ACTUAL",{"date":75,"type":73},"2025-09-10",{"date":77,"type":62},"2030-10",{"name":5,"class":6},1]